Jacobshagen, Claudius

[["dc.bibliographiccitation.firstpage","337"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","344"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Westermann, D."],["dc.contributor.author","Holubarsch, C."],["dc.contributor.author","Böhm, M."],["dc.date.accessioned","2019-07-09T11:52:26Z"],["dc.date.available","2019-07-09T11:52:26Z"],["dc.date.issued","2010"],["dc.description.abstract","This article gives an overview on a number of novel clinical trials in the field of cardiovascular medicine, which were presented during the Late Breaking Clinical Trial Sessions at the 59th annual meeting of the American College of Cardiology in Atlanta, USA, from 14th March to 16th March 2010. The data were presented by leading experts in the field with relevant positions in the trials. These comprehensive summaries should provide the readers with the most recent data on diagnostic and therapeutic developments in cardiovascular medicine similar as previously reported (Schirmer SH, van der Laan AM, Bohm M, Mahfoud F in Clin Res Cardiol 98:691–699, 2009; Maier LS, Schirmer SH, Walenta K, Jacobshagen C, Bohm M in Clin Res Cardiol 98:413–419, 2009)."],["dc.identifier.doi","10.1007/s00392-010-0154-6"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4242"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60188"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","427"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Thrombosis and Thrombolysis"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Koltowski, Lukasz"],["dc.contributor.author","Tomaniak, Mariusz"],["dc.contributor.author","Gross, Lisa"],["dc.contributor.author","Rymuza, Bartosz"],["dc.contributor.author","Kowara, Michal"],["dc.contributor.author","Parma, Radoslaw"],["dc.contributor.author","Komosa, Anna"],["dc.contributor.author","Klopotowski, Mariusz"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Gori, Tommaso"],["dc.contributor.author","Aradi, Daniel"],["dc.contributor.author","Huber, Kurt"],["dc.contributor.author","Hadamitzky, Martin"],["dc.contributor.author","Massberg, Steffen"],["dc.contributor.author","Lesiak, Maciej"],["dc.contributor.author","Filipiak, Krzysztof J."],["dc.contributor.author","Witkowski, Adam"],["dc.contributor.author","Opolski, Grzegorz"],["dc.contributor.author","Huczek, Zenon"],["dc.contributor.author","Sibbing, Dirk"],["dc.date.accessioned","2019-07-09T11:51:05Z"],["dc.date.available","2019-07-09T11:51:05Z"],["dc.date.issued","2019"],["dc.description.abstract","To investigate the safety and efficacy of an early platelet function testing (PFT)-guided de-escalation of dual antiplatelet treatment (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with bioresorbable vascular scaffolds (BVS). Early DAPT de-escalation is a new non-inferior alternative to 12-months DAPT in patients with biomarker positive ACS treated with stent implantation. In this post-hoc analysis of the TROPICAL-ACS trial, which randomized 2610 ACS patients to a PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel) or to control group (uniform prasugrel), we compared clinical outcomes of patients (n = 151) who received a BVS during the index PCI. The frequency of the primary endpoint (cardiovascular death, myocardial infarction, stroke or BARC ≥ 2 bleeding) was 8.8% (n = 6) in the de-escalation group vs. 12.0% (n = 10) in the control group (HR 0.72, 95% CI 0.26-1.98, p = 0.52) at 12 months. One early definite stent thrombosis (ST) occurred in the control group (day 19) and 1 possible ST (sudden cardiovascular death) in the de-escalation group (day 86), both despite prasugrel treatment and in a background of high on-treatment platelet reactivity assessed at day 14 after randomization (ADP-induced platelet aggregation values of 108 U and 59 U, respectively). A PFT-guided DAPT de-escalation strategy could potentially be a safe and effective strategy in ACS patients with BVS implantation but the level of platelet inhibition may be of particular importance. This hypothesis-generating post-hoc analysis requires verification in larger studies with upcoming BVS platforms."],["dc.identifier.doi","10.1007/s11239-019-01811-2"],["dc.identifier.pmid","30739305"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16046"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59873"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]